DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR OLANZAPINE
All Clinical Trials for Olanzapine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000373 | Treatment of Obsessive-Compulsive Disorder | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 1992-09-01 | The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial. |
| NCT00000373 | Treatment of Obsessive-Compulsive Disorder | Completed | University of Florida | Phase 4 | 1992-09-01 | The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial. |
| NCT00000374 | Treatment for First-Episode Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 1998-09-01 | This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia. |
| NCT00000374 | Treatment for First-Episode Schizophrenia | Completed | The Zucker Hillside Hospital | Phase 4 | 1998-09-01 | This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia. |
| NCT00000374 | Treatment for First-Episode Schizophrenia | Completed | Northwell Health | Phase 4 | 1998-09-01 | This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Olanzapine
Condition Name
Condition MeSH
Clinical Trial Locations for Olanzapine
Trials by Country
Clinical Trial Progress for Olanzapine
Clinical Trial Phase
Clinical Trial Sponsors for Olanzapine
Sponsor Name
